Fulcrum Therapeutics, Inc.

Contributing Author

Recent Articles by Fulcrum Therapeutics, Inc.

Mar-06	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) FULC GlobeNewswire
Mar-03	Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference FULC GlobeNewswire
Feb-24	Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025 FULC -21.21% GlobeNewswire
Feb-24	Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease FULC -21.21% GlobeNewswire
Feb-17	Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease FULC GlobeNewswire
Feb-06	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) FULC +5.03% FULC GlobeNewswire
Jan-09	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) FULC GlobeNewswire
Jan-07	Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference FULC GlobeNewswire
Dec-10	Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants FULC -5.48% GlobeNewswire
Dec-08	Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock FULC +45.96% FULC +12.39% GlobeNewswire
Dec-06	Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting FULC GlobeNewswire
Dec-05	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) FULC +45.96% FULC GlobeNewswire
Dec-02	Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025 FULC -9.32% GlobeNewswire
Nov-07	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) FULC GlobeNewswire
Nov-03	Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting FULC -7.21% FULC GlobeNewswire
Oct-29	Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025 FULC -6.40% GlobeNewswire
Oct-22	Fulcrum Therapeutics to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Wednesday, October 29, 2025, at 8:00 a.m. ET FULC -6.80% GlobeNewswire
Oct-14	Fulcrum Therapeutics to Present Preclinical Data for EED Inhibitor FTX-6274 at European Society for Medical Oncology (ESMO) Congress 2025 FULC GlobeNewswire
Oct-10	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) FULC -6.55% GlobeNewswire
Sep-12	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) FULC GlobeNewswire
Aug-26	Fulcrum Therapeutics to Present at Upcoming Investor Meetings FULC GlobeNewswire
Aug-08	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) FULC GlobeNewswire
Jul-29	Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025 FULC GlobeNewswire
Jul-29	Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease FULC GlobeNewswire
Jul-28	Fulcrum Therapeutics to Present Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease FULC GlobeNewswire
Jul-11	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) FULC GlobeNewswire
Jun-06	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) FULC GlobeNewswire
May-29	Fulcrum Therapeutics to Present at Upcoming Medical Meetings FULC GlobeNewswire
May-29	Fulcrum Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference FULC GlobeNewswire
May-09	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) FULC +5.77% FULC GlobeNewswire
May-08	Fulcrum Therapeutics to Participate in Upcoming May Conferences FULC +6.71% GlobeNewswire

Fulcrum Therapeutics, Inc.

Recent Articles by Fulcrum Therapeutics, Inc.

Upgrade your FINVIZ experience